Ipratropium Viatris

Ipratropium bromide, the active ingredient in Ipratropium Viatris, is an anticholinergic (muscarinic antagonist) presented as an inhalation formulation for inhalation use. It is used to treat chronic obstructive pulmonary disease and asthma by relaxing airway smooth muscle and reducing mucus secretion.

GNH USA supplies Ipratropium Viatris as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ipratropium Viatris acts on the muscarinic receptors of the respiratory tract to provide bronchodilation and mucus control.

- Chronic obstructive pulmonary disease (COPD): improves airflow, reduces exacerbations, and eases breathing difficulty. - Asthma: provides bronchodilation, helps control symptoms, and reduces airway secretions. - Bronchospasm: delivers rapid relief of airway constriction during acute episodes.

Ipratropium bromide may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dry mouth: reduced salivation leading to throat discomfort. - Cough: irritation of the airway during inhalation. - Throat irritation: mild soreness or burning sensation. - Headache: transient mild headache. - Dizziness: occasional light‑headed feeling. - Nausea: occasional upset stomach.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of breathing. - Allergic reaction: rash, itching, swelling, or angioedema. - Severe tachycardia: rapid heart rate requiring medical attention. - Urinary retention: difficulty emptying the bladder. - Exacerbation of narrow‑angle glaucoma: increased intra‑ocular pressure.

Before prescribing Ipratropium Viatris, clinicians should evaluate patient‑specific factors and monitor for potential complications.

- Assess renal function: dose may need adjustment in severe renal impairment. - Monitor anticholinergic effects: watch for dry mouth, urinary retention, or constipation. - Use caution in narrow‑angle glaucoma: may worsen intra‑ocular pressure. - Avoid in patients with known hypersensitivity to ipratropium bromide. - Pregnancy: safety not established; prescriber should weigh benefits and risks. - Store at room temperature: keep in original container, protect from moisture and light.

Ipratropium bromide can interact with other medications, altering its safety profile or efficacy.

Major Interactions (Avoid): - Concurrent anticholinergic inhalers: may increase anticholinergic load and side‑effects. - Beta‑agonists: additive bronchodilation can lead to tachycardia or arrhythmia. - MAO inhibitors: potential for heightened cholinergic side‑effects.

Moderate Interactions (Monitor Closely): - Antihistamines: may enhance anticholinergic effects such as dry mouth. - Tricyclic antidepressants: increased anticholinergic burden. - Theophylline: monitor for additive respiratory effects and possible toxicity.